Novel PET composite incorporating bacterial cellulose nanocrystals (BCNC) to reduce oxygen permeability and enhance biodegradability of food and beverage containers. Surface grafting with lactic acid and poly(ethylene oxide) further improves barrier performance and moisture repellence for recyclable packaging applications.
This research proposes a novel biopolymer composite that incorporates bacterial cellulose nanocrystals (BCNC) derived from Acetobacter and Lactobacillus into PET containers through extrusion blow moulding. The addition of BCNC aims to reduce oxygen permeability, improve moisture repellence, and enhance biodegradability of food and beverage packaging. By varying BCNC concentrations and applying surface grafting treatments, the project seeks to develop recyclable PET containers with superior barrier properties compared to conventional packaging.
The technology addresses growing industry demand for sustainable packaging solutions that maintain product shelf-life performance while reducing environmental impact. Potential applications include food and beverage containers, pharmaceutical packaging, and other applications requiring oxygen-sensitive product protection.
Core innovation:
Key performance targets:
Technical advantages:
This research is at an early experimental stage (TRL 2-3). The project involves laboratory-scale fabrication and characterization of PET/BCNC composites through extrusion and moulding processes. Validation will include controlled comparison testing of 48 experimental PET containers against 3 control containers (without additive) to measure oxygen permeability differences across varying BCNC concentrations and surface grafting treatments. The research builds on validated prior work demonstrating that cellulose nanocrystals can enhance O2 and CO2 barrier properties in PLA matrices.
Swinburne University of Technology is a public research university with a technology focus and a multi‑campus footprint across metropolitan Melbourne. Industry partners access co‑located laboratories, pilot‑scale testbeds, and an innovation precinct that supports rapid prototyping, validation, and scale‑up. Work‑integrated learning and co‑op style placements, industry‑embedded PhDs, and executive education provide pipelines for talent and problem‑led collaboration, complemented by shared‑use equipment and contract R&D. Research is supported by competitive Australian federal and state funding, including the Australian Research Council and National Health and Medical Research Council. A dedicated commercialization office manages IP strategy, licensing, and spin‑outs, with streamlined agreements that enable faster engagement.